Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CYFIP related Rac1 interactor A (CYRIA/FAM49A) is a cytosolic protein that regulates cellular actin polymerization through direct interaction with **active Rac1** small GTPase[1][2][6][7]. By competing with the WAVE regulatory complex (WRC) for Rac1 binding, CYRIA negatively regulates Rac1 signaling, affecting actin-driven processes such as **cell motility, chemotaxis, cell migration, membrane protrusion formation, and epithelial polarization**[1][7]. CYRIA is structurally homologous to CYFIP proteins (CYFIP1/CYFIP2), sharing the DUF1394 domain, and is highly conserved evolutionarily[1][3]. Altered CYRIA expression has been implicated in cancer progression, particularly promoting cell proliferation and invasiveness when downregulated[1]. CYRIA also contributes to the regulation of immune cell function and host response to bacterial infection by modulating cytoskeletal rearrangement required for pathogen entry[1]. CYRIA has no current direct therapeutic targeting or approved interacting drugs, but may represent a novel candidate for future pharmacological modulation in diseases relating to cytoskeletal remodeling, migration, or infection[2][7][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CYFIP related Rac1 interactor A (CYRIA).